New Product Release

Genovis will launch two new products, FragIT™ MicroSpin and deGlycIT™ MicroSpin  during the European Antibody Engineering Congress 2010 in Geneva. Both products has been developed from Genovis’ unique enzyme techniques and target pharma-, biotechnology- and diagnostic companies that develop antibody based drugs and analysis.

Read more at:

The Product Release is attached and published at Genovis web site:

Find out more, contact: Sarah Fredriksson, CEO, Genovis AB Tel: +46 46 10 12 35

Genovis is a biotech company on the leading edge of nanotechnology and nanoparticles. The company’s patented nano-induced magnetic transfer (NIMT®) technology was developed to facilitate effective preclinical research for the life science industry. Genovis shares are listed on Nasdaq OMX First North and Thenberg & Kinde Fondkommission is our certified adviser.

About Us

Genovis’ business concept is to develop, produce and market innovative technologies that facilitate and enable development of new treatment methods and diagnostics for customers in the medical device and pharmaceutical industries. The Group consists of Genovis AB and the subsidiary GeccoDots AB. Genovis develops and sells unique enzymes (protein engineering portfolio) in innovative product formats that facilitate development and quality control of and biological drugs. GeccoDots uses nanotechnology to produce a new type of contrast agent that is used in medical imaging. Genovis shares are listed on NASDAQ OMX First North


Documents & Links